PBM Formulary Exclusions In Oncology Are On The Rise
Physician-Administered Drugs Make Up Nearly Half Of Oncology Exclusions
Executive Summary
Oncology drugs are no longer immune to pharmacy benefit management formulary exclusions in the commercial market and even drugs administered in a physician’s office are increasingly being subjected to rebate-driven coverage decisions.
You may also be interested in...
The Booming Business Of Drug Exclusions
The number of drugs included on formulary exclusion lists in the US has surpassed more than 400 at the top three PBMs, representing dramatic growth from just five years ago. Express Scripts recently revealed its 2022 exclusions.
Medical Benefit, Hospital Drugs Exempt From Detailed Cost, Coverage Reporting In Final Rule
The most detailed US reporting requirements regarding prescription drug costs and coverage will target medicines reimbursed under the retail pharmacy benefit.
Pfizer Getting $529 Per Course For Paxlovid Under US Contract; Did Merck Drive A Harder Bargain?
US government is paying Merck & Co. around $181 more per course of treatment for its oral antiviral for COVID-19, molnupiravir, than it is to Pfizer for its competing drug.